Skip to main content
Premium Trial:

Request an Annual Quote

Robert Stein Resigns from Incyte; Jeremy Berg is New NIGMS Director; Catherine Burzik Joins ABI; New Management at Pyrosequencing; and Others

Robert Stein has resigned from his position as president and CSO of Incyte to take a "senior position at a leading west coast life science company," according to a company statement.


Stein has been with Incyte since 2001, when he joined the company from DuPont Pharmaceuticals along with Incyte CEO Paul Friedman.


Meanwhile, Incyte has tapped Richard Levy as senior vice president, drug development. Levy has held prior executive-level positions at Celgene, DuPont Pharmaceuticals, and Novartis.


Jeremy Berg, currently director of the Institute for Basic Biomedical Sciences and professor and director of the department of biophysics and biophysical chemistry at Johns Hopkins University School of Medicine in Baltimore, has been named as the new director of the National Institute of General Medical Sciences.


Berg is expected to begin his new position in early November.


As NIGMS director, Berg will oversee a $1.8 billion budget that funds basic research in the areas of cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, bioinformatics, and computational biology.


NIGMS currently supports more than 4,400 research grants -- about 10 percent of the grants funded by NIH as a whole.



Catherine Burzik has been appointed executive vice president of Applied Biosystems and a member of ABI parent company Applera's management executive committee.


Burzik, who most recently served as president of Ortho-Clinical Diagnostics, will report to Michael Hunkapiller, president of ABI.


The appointment is effective September 2, 2003.


Burzik will be responsible for ABI's product management organizations -- including DNA Platforms, Discovery Proteomics, Small Molecule, and the Knowledge Business - as well as sales and service, marketing, business development, and strategic planning. Other functions, including research and product development, operations, finance, and legal affairs, will continue to report directly to Hunkapiller.



In the wake of its announced merger with Personal Chemistry, which is expected to close on Sept. 25, 2003, Pyrosequencing has appointed a new management team.


Jeff Bork will continue as chairman of the board and CEO of Pyrosequencing, while Hans Johansson, currently president of Personal Chemistry, will become president and COO of the merged entity. Mats-Olof Wallin and Marten Winge will continue as CFO and vice president of marketing, respectively. Jon-Sverre Schanche, currently vice president of R&D at Personal Chemistry, will be vice president of R&D. Scott Carr, head of Personal Chemistry's American sales company, will become president of the merged US subsidiaries.


Erik Wallden, currently the president of Pyrosequencing, has "requested to be relieved from his duties," the company said. He will leave the company on Sept. 25, 2003.



CytRx has hired three new senior executives for its management team from The Kriegsman Group, a Los Angeles-based investment bank.


Ed Umali, formerly managing director with The Kriegsman Group, will become director of operations at CytRx; David Haen will become director of business development; and Carolyn French will become director of communications.


French's position at CytRx is on a full-time basis, while Umali and Haen are expected to continue to provide certain services to The Kriegsman Group on a limited basis.



Kary Mullis, who received a Nobel Prize in chemistry in 1993 for inventing PCR, has joined the scientific advisory board of CalbaTech, an Irvine-Calif.-based life science incubator.


"We are delighted that a scientist with Dr. Mullis' enormous accomplishments, combined with his expertise in the life science arena, has agreed to contribute to our scientific advisory board," said James DeOlden, CEO of CalbaTech. "There simply is no other scientist with his combination of scientific know-how and business acumen, and this appointment is a major step forward for CalbaTech."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.